Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Monoethanolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Monoethanolamine SCHEMBL9809181 | 0.96 | — | — | |
| Monoethanolamine SCHEMBL5985807 | 0.82 | — | — | |
| Monoethanolamine SCHEMBL10941117 | 0.82 | TSHR (1.00) | TSHRALDH1A1 | |
| Monoethanolamine SCHEMBL1331364 | 0.82 | — | — | |
| Monoethanolamine SCHEMBL8339880 | 0.82 | TSHR (1.00) | TSHRALDH1A1 | |
| Monoethanolamine SCHEMBL1644 | 0.82 | — | — | |
| Monoethanolamine SCHEMBL1332111 | 0.82 | — | — | |
| Monoethanolamine SCHEMBL14675689 | 0.82 | TSHR (1.00) | TSHRALDH1A1 | |
| Monoethanolamine SCHEMBL29663853 | 0.82 | — | — | |
| Monoethanolamine SCHEMBL4937454 | 0.82 | TSHR (1.00) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026896-A1 | Platinum(II) and platinum(IV) complexes and their use | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026896-A1 | Platinum(II) and platinum(IV) complexes and their use | XPA, XPOT, POLN | TSHR 1095/4885ALDH1A1 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.